Anzeige
Mehr »
Login
Freitag, 03.05.2024 Börsentäglich über 12.000 News von 685 internationalen Medien
Schnelle Produktionsaufnahme: Multi-Tenbagger-Potenzial direkt in Spanien?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
33 Leser
Artikel bewerten:
(0)

Global Endometrial Cancer Therapeutics Market to Reach $27 Billion by 2021 - Rising Global Endometrial Cancer Epidemics - Research and Markets

DUBLIN, May 29, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Endometrial Cancer Therapeutics Market, Outlook to 2023" report to their offering.

Research and Markets Logo

The Endometrial Cancer therapeutics market is poised to reach approximately US$ 27 Billion by 2023. In this report, there is in-depthmarket analysis as well as market segmentation of global endometrial cancer therapeutics. The market potential of endometrial cancer therapeutic drugsisestimated considering that these are being tested in clinical trials for endometrial cancer, besides the ones which have already been approved. The depictedendometrial cancer therapeutic drugsare expected to show their complete market potential soon in the coming years.

Furthermore, in this report we have structured the information on epidemiology of endometrial cancer in the world. The report also covers pipeline analysis of endometrial cancer therapeutic drugs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments,as well as strategic collaborations that can impact industry's growth.


Key Market Drivers:

  • Rising Global Endometrial Cancer Epidemics
  • Obesity Fuelling Endometrial Cancer Incidences
  • Increasing Healthcare Expenditure

Companies Mentioned

  • ArQule, Inc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffman La Roche Ltd.
  • GlaxoSmithKline plc
  • Merck KGaA
  • Novartis AG
  • Sanofi
  • Takeda Pharmaceutical Company Limited

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Endometrial Cancer - Epidemiology & Risk Factors

4. Endometrial Cancer Therapeutics - An Introduction

5. Market Dynamics

6. Endometrial Cancer Therapeutics Market Outlook to 2023

7. Market Segmentation

8. Endometrial Cancer Therapeutic Drugs Pipeline Analysis

9. Trends and Developments

10. Strategic Mergers & Collaborations in the Endometrial Cancer Therapeutics Industry

11. Competitive Assessment

For more information about this report visit http://www.researchandmarkets.com/research/xnbr78/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2017 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.